董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joshua Resnick | 男 | Director | 50 | 27.58万美元 | 未持股 | 2025-02-07 |
| Laurie Stelzer | 女 | Director | 58 | 29.96万美元 | 未持股 | 2025-02-07 |
| Lucian Iancovici | 男 | Director | 43 | 未披露 | 未持股 | 2025-02-07 |
| Michael Cloonan | 男 | Chief Executive Officer, President and Director | 54 | 698.12万美元 | 94.72 | 2025-02-07 |
| Marcella Kuhlman Ruddy | 女 | Director | 63 | 80.36万美元 | 未持股 | 2025-02-07 |
| Paul Clancy | 男 | Chairperson of the Board | 64 | 32.31万美元 | 8.99 | 2025-02-07 |
| H. Edward Fleming, Jr. | 男 | Director | 62 | 28.30万美元 | 未持股 | 2025-02-07 |
| Joanne Louise Viney | 女 | Director | 60 | 81.03万美元 | 未持股 | 2025-02-07 |
| Peter A. Thompson | 男 | Director | 66 | 27.99万美元 | 未持股 | 2025-02-07 |
| Bruce Booth | 男 | Director | 50 | 28.12万美元 | 未持股 | 2025-02-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elena Ridloff | 女 | Chief Financial Officer and Head of Corporate Development | 45 | 285.74万美元 | 24.89 | 2025-02-07 |
| Michael Cloonan | 男 | Chief Executive Officer, President and Director | 54 | 698.12万美元 | 94.72 | 2025-02-07 |
| Charlotte McKee | -- | Chief Medical Officer | 61 | 128.32万美元 | 14.12 | 2025-02-07 |
董事简历
中英对照 | 中文 | 英文- Joshua Resnick
-
Joshua Resnick自2019年2月以来一直担任我们的董事会成员。Resnick博士目前担任RA Capital Management的董事总经理，自2018年10月起担任该职位。Resnick博士此前曾于2016年1月至2018年9月担任SV Health Investors的合伙人，并于2014年至2016年1月担任MRL Ventures Fund的总裁兼管理合伙人，该基金是他在默克公司（Merck&Co.）内部建立和管理的专注于治疗的早期企业风险基金。Resnick博士在马萨诸塞州总医院（Massachusetts General Hospital）急诊医学部工作。Resnick博士分别于2016年11月至2018年9月和2016年7月至2018年9月担任KalVistaPharmaceuticals，Inc.和AVROBIO，Inc.的董事会成员。Resnick博士在威廉姆斯学院（Williams College）获得化学学士学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
Joshua Resnick,has served as a member of Sionna Therapeutics, Inc. board of directors since December 2019. Dr. Resnick is a senior managing director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August 2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania. - Joshua Resnick自2019年2月以来一直担任我们的董事会成员。Resnick博士目前担任RA Capital Management的董事总经理，自2018年10月起担任该职位。Resnick博士此前曾于2016年1月至2018年9月担任SV Health Investors的合伙人，并于2014年至2016年1月担任MRL Ventures Fund的总裁兼管理合伙人，该基金是他在默克公司（Merck&Co.）内部建立和管理的专注于治疗的早期企业风险基金。Resnick博士在马萨诸塞州总医院（Massachusetts General Hospital）急诊医学部工作。Resnick博士分别于2016年11月至2018年9月和2016年7月至2018年9月担任KalVistaPharmaceuticals，Inc.和AVROBIO，Inc.的董事会成员。Resnick博士在威廉姆斯学院（Williams College）获得化学学士学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）获得医学博士学位，在沃顿商学院（Wharton School of Business）获得工商管理硕士学位。
- Joshua Resnick,has served as a member of Sionna Therapeutics, Inc. board of directors since December 2019. Dr. Resnick is a senior managing director at RA Capital Management, L.P., where he previously served as a Managing Director from October 2018 to March 2023. Dr. Resnick is also a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Dr. Resnick has served on the boards of directors of PepGen Inc. (NASDAQ: PEPG) since November 2020, Aerovate Therapeutics, Inc. (NASDAQ: AVTE) since August 2020, as well as from October 2018 to February 2020, and Vor Biopharma Inc. (NASDAQ: VOR) since February 2019. Dr. Resnick received a B.A. in chemistry from Williams College, an M.D. from the University of Pennsylvania Perelman School of Medicine and an M.B.A. from The Wharton School of the University of Pennsylvania.
- Laurie Stelzer
-
Laurie Stelzer自2020年8月起担任我们的董事会成员。Stelzer女士曾担任ArenaPharmaceuticals，Inc.执行Vice President和首席财务官纳斯达克:ARNA，生物制药公司，自2020年3月起。她还自2018年1月起担任临床阶段免疫肿瘤公司SurfaceOncology，Inc.（纳斯达克股票代码:SURF）的董事会成员。在加入Arena Pharmaceuticals之前，Stelzer女士于2015年6月至2020年3月担任生物制药技术平台公司HalozymeTherapeutics，Inc.（纳斯达克股票代码:HALO）的首席财务官，领导财务，信息技术，业务开发，项目管理和现场运营组织。在加入Halozyme Therapeutics之前，Stelzer女士曾在Shire plc（被武田收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官和投资者关系主管。此前，她也曾任职Amgen，Inc.（纳斯达克股票代码:AMGN）（全球生物制药公司）15年，担任财务、财政、全球会计和国际/新兴市场领域的责任日益增加的职务。Stelzer女士在亚利桑那州立大学（Arizona State University）获得会计学学士学位，并在加州大学洛杉矶分校安德森管理学院（Anderson School of Management）获得工商管理硕士学位。
Laurie Stelzer,has served as a member of Sionna Therapeutics, Inc. board of directors since November 2024. Ms. Stelzer has served as the Chief Financial Officer of Kailera Therapeutics, Inc. ("Kailera") since January 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics ("Orna") from May 2024 to January 2025. Prior to Orna, Ms. Stelzer served as the Chief Financial Officer of ReNAgade Therapeutics, Inc. ("ReNAgade") from September 2023 until the completion of its acquisition by Orna in May 2024. Prior to joining ReNAgade, Ms. Stelzer served as the Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX) ("Mirati Therapeutics") from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena Pharmaceuticals") (acquired by Pfizer) from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as the Chief Financial Officer at Halozyme Therapeutics, Inc. ("Halozyme Therapeutics") (Nasdaq: HALO) from June 2015 to March 2020, and before Halozyme Therapeutics, she held senior management roles at Shire Plc (acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK)) and Amgen, Inc. Ms. Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) since 2020, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since 2023, Surface Oncology, Inc. (Nasdaq: SURF) from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management. - Laurie Stelzer自2020年8月起担任我们的董事会成员。Stelzer女士曾担任ArenaPharmaceuticals，Inc.执行Vice President和首席财务官纳斯达克:ARNA，生物制药公司，自2020年3月起。她还自2018年1月起担任临床阶段免疫肿瘤公司SurfaceOncology，Inc.（纳斯达克股票代码:SURF）的董事会成员。在加入Arena Pharmaceuticals之前，Stelzer女士于2015年6月至2020年3月担任生物制药技术平台公司HalozymeTherapeutics，Inc.（纳斯达克股票代码:HALO）的首席财务官，领导财务，信息技术，业务开发，项目管理和现场运营组织。在加入Halozyme Therapeutics之前，Stelzer女士曾在Shire plc（被武田收购）担任高级管理职务，包括财务高级副总裁、再生医学部门的部门首席财务官和投资者关系主管。此前，她也曾任职Amgen，Inc.（纳斯达克股票代码:AMGN）（全球生物制药公司）15年，担任财务、财政、全球会计和国际/新兴市场领域的责任日益增加的职务。Stelzer女士在亚利桑那州立大学（Arizona State University）获得会计学学士学位，并在加州大学洛杉矶分校安德森管理学院（Anderson School of Management）获得工商管理硕士学位。
- Laurie Stelzer,has served as a member of Sionna Therapeutics, Inc. board of directors since November 2024. Ms. Stelzer has served as the Chief Financial Officer of Kailera Therapeutics, Inc. ("Kailera") since January 2025. Prior to Kailera, Ms. Stelzer served as the Chief Financial Officer of Orna Therapeutics ("Orna") from May 2024 to January 2025. Prior to Orna, Ms. Stelzer served as the Chief Financial Officer of ReNAgade Therapeutics, Inc. ("ReNAgade") from September 2023 until the completion of its acquisition by Orna in May 2024. Prior to joining ReNAgade, Ms. Stelzer served as the Chief Financial Officer of Mirati Therapeutics, Inc. (Nasdaq: MRTX) ("Mirati Therapeutics") from May 2022 to September 2023. Prior to joining Mirati Therapeutics, Ms. Stelzer served as the Executive Vice President and Chief Financial Officer of Arena Pharmaceuticals, Inc. ("Arena Pharmaceuticals") (acquired by Pfizer) from March 2020 until the completion of Pfizer's acquisition in March 2022. Prior to joining Arena Pharmaceuticals, Ms. Stelzer served as the Chief Financial Officer at Halozyme Therapeutics, Inc. ("Halozyme Therapeutics") (Nasdaq: HALO) from June 2015 to March 2020, and before Halozyme Therapeutics, she held senior management roles at Shire Plc (acquired by Takeda Pharmaceuticals Company Limited (NYSE: TAK)) and Amgen, Inc. Ms. Stelzer has served as a member of the board of directors of PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) since 2020, Spyre Therapeutics, Inc. (Nasdaq: SYRE) since 2023, Surface Oncology, Inc. (Nasdaq: SURF) from 2018 until its acquisition by Coherus in September 2023 and Longboard Pharmaceuticals from 2020 to 2021. Ms. Stelzer received her B.S. in Accounting from Arizona State University and her M.B.A. from University of California, Los Angeles, Anderson School of Management.
- Lucian Iancovici
-
Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University. - Lucian Iancovici自2020年5月起担任我们的董事会成员。Iancovici博士目前是TPG Growth的董事总经理，自2018年1月起在该公司工作。从2012年9月到2017年10月，Iancovici博士担任高通生命基金（Qualcomm Life Fund）的负责人，该基金是一家专注于投资数字健康技术的风险基金。从2015年1月到2017年10月，Iancovici博士是DRX Capital的普通合伙人，DRX Capital是一家由诺华和高通发起的合资投资公司。从2011年到2012年，Iancovici博士是麦肯锡公司的助理。Lucian是一名董事会认证的内科医生，在加入麦肯锡公司之前曾在纽约哥伦比亚大学医疗中心接受培训。Iancovici博士在塔夫茨大学获得了经济学学士学位和硕士学位。
- Lucian Iancovici has served as a member of Rallybio's Board since May 2020. Dr. Iancovici is currently a Partner of TPG, a global alternative asset manager, where he has worked since January 2018. From September 2012 to October 2017, Dr. Iancovici served as the head of the Qualcomm Life Fund, a venture fund focused on investing in digital health technologies. From January 2015 to October 2017, Dr. Iancovici was a general partner at dRx Capital, a joint venture investment company launched by Novartis and Qualcomm. From 2011 to 2012, Dr. Iancovici was an associate at McKinsey & Company. Dr. Iancovici currently serves on the board of directors of Sionna Therapeutics, Inc. and on the boards of directors of several private companies. He is a board certified internal medicine doctor who trained at Columbia University Medical Center in New York prior to joining McKinsey & Company. Dr. Iancovici received his B.A. in economics and an M.D., both from Tufts University.
- Michael Cloonan
-
Michael Cloonan，自2024年起在bluebird bio, Inc.董事会任职。自2021年5月以来，Cloonan先生在Sionna Therapeutics担任总裁兼首席执行官，领导公司战略和运营。2017年5月至2021年4月，Cloonan先生在Sage Therapeutics担任首席运营官，领导所有业务职能（商业、医疗事务、政府事务、业务发展、技术运营、战略和项目管理）以及一般和行政职能。在加入Sage之前，Cloonan先生在渤健担任了十四年的各种商业和商业职务，包括最近担任美国商业高级副总裁，担任价值数十亿美元的多发性硬化症、血友病和脊髓性肌萎缩症特许经营权的总经理。在加入渤健之前，Cloonan先生曾在贝恩公司担任顾问，专门从事医疗保健方面的工作。克鲁南先生获得了弗吉尼亚大学达顿工商管理研究生院的工商管理硕士学位和圣十字学院的学士学位。
Michael Cloonan,has served as Sionna Therapeutics, Inc. President, Chief Executive Officer and a member of Sionna Therapeutics, Inc. board of directors since May 2021. Previously, Mr. Cloonan served as the Chief Operating Officer of Sage Therapeutics, Inc. (NASDAQ: SAGE) ("Sage") from May 2020 to May 2021, and as the chief business officer of Sage from April 2017 to May 2020. Prior to joining Sage, Mr. Cloonan served in various leadership positions at Biogen, Inc. (NASDAQ: BIIB) ("Biogen") in various business and commercial roles in his fourteen years at Biogen. His most recent role at Biogen was as senior vice president, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia and SMA franchises. Mr. Cloonan has also served on the board of directors of bluebird bio, Inc. (NASDAQ: BLUE) since June 2024. Mr. Cloonan earned a B.A. in economics and accounting from the College of the Holy Cross and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia. - Michael Cloonan，自2024年起在bluebird bio, Inc.董事会任职。自2021年5月以来，Cloonan先生在Sionna Therapeutics担任总裁兼首席执行官，领导公司战略和运营。2017年5月至2021年4月，Cloonan先生在Sage Therapeutics担任首席运营官，领导所有业务职能（商业、医疗事务、政府事务、业务发展、技术运营、战略和项目管理）以及一般和行政职能。在加入Sage之前，Cloonan先生在渤健担任了十四年的各种商业和商业职务，包括最近担任美国商业高级副总裁，担任价值数十亿美元的多发性硬化症、血友病和脊髓性肌萎缩症特许经营权的总经理。在加入渤健之前，Cloonan先生曾在贝恩公司担任顾问，专门从事医疗保健方面的工作。克鲁南先生获得了弗吉尼亚大学达顿工商管理研究生院的工商管理硕士学位和圣十字学院的学士学位。
- Michael Cloonan,has served as Sionna Therapeutics, Inc. President, Chief Executive Officer and a member of Sionna Therapeutics, Inc. board of directors since May 2021. Previously, Mr. Cloonan served as the Chief Operating Officer of Sage Therapeutics, Inc. (NASDAQ: SAGE) ("Sage") from May 2020 to May 2021, and as the chief business officer of Sage from April 2017 to May 2020. Prior to joining Sage, Mr. Cloonan served in various leadership positions at Biogen, Inc. (NASDAQ: BIIB) ("Biogen") in various business and commercial roles in his fourteen years at Biogen. His most recent role at Biogen was as senior vice president, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia and SMA franchises. Mr. Cloonan has also served on the board of directors of bluebird bio, Inc. (NASDAQ: BLUE) since June 2024. Mr. Cloonan earned a B.A. in economics and accounting from the College of the Holy Cross and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
- Marcella Kuhlman Ruddy
-
Marcella Kuhlman Ruddy，自2023年1月起担任Upstream Bio，Inc.董事会成员。自2021年7月起，Ruddy博士担任Tectonic Therapeutic，Inc.的首席医疗官。从2016年6月至2021年6月，Ruddy博士在再生元制药，Inc.担任免疫学/炎症治疗领域的临床开发主管。此前，Ruddy博士曾在2004年11月至2014年6月期间在默沙东担任越来越重要的职务，包括免疫学早期临床开发主管。从2015年11月到2016年6月，Ruddy博士在Alnylam Pharmaceuticals, Inc.担任临床开发副总裁兼药物警戒负责人。从2014年6月到2014年11月，Ruddy博士在医疗保健业务EMD Serono，Inc.担任临床免疫学副总裁。从1996年6月到2004年10月，Ruddy博士在麻省总医院/哈佛医学院肺科担任职员职位，在那里她创立并指导了成人囊性纤维化项目。Ruddy博士拥有普林斯顿大学的学士学位和圣路易斯华盛顿大学的医学博士和医学硕士学位，并在哈佛医学院附属医院完成了她的内科和肺部研究金培训。
Marcella Kuhlman Ruddy,has served as a member of Sionna Therapeutics, Inc. board of directors since January 2025. Dr. Ruddy has over 20 years of experience in drug development. Dr. Ruddy has served as the chief medical officer of Tectonic Therapeutic, Inc. (NASDAQ: TECX) since July 2021. From June 2016 to June 2021, Dr. Ruddy served as vice president of clinical development, immunology at Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), where she oversaw the clinical development of Dupixent. She is a trained pulmonologist who founded and led the Adult Cystic Fibrosis center at Massachusetts General Hospital, Boston from 1999-2004 prior to starting her drug development career at Merck & Co Inc. (NYSE: MRK). Dr. Ruddy has served on the board of directors of Upstream Bio, Inc. (NASDAQ: UPB) since January 2023. Dr. Ruddy previously served on the board of directors of Polarean, Inc. from August 2022 to June 2024. Dr. Ruddy received her B.A. in history from Princeton University and her M.D. and M.S. from Washington University, School of Medicine, St. Louis. - Marcella Kuhlman Ruddy，自2023年1月起担任Upstream Bio，Inc.董事会成员。自2021年7月起，Ruddy博士担任Tectonic Therapeutic，Inc.的首席医疗官。从2016年6月至2021年6月，Ruddy博士在再生元制药，Inc.担任免疫学/炎症治疗领域的临床开发主管。此前，Ruddy博士曾在2004年11月至2014年6月期间在默沙东担任越来越重要的职务，包括免疫学早期临床开发主管。从2015年11月到2016年6月，Ruddy博士在Alnylam Pharmaceuticals, Inc.担任临床开发副总裁兼药物警戒负责人。从2014年6月到2014年11月，Ruddy博士在医疗保健业务EMD Serono，Inc.担任临床免疫学副总裁。从1996年6月到2004年10月，Ruddy博士在麻省总医院/哈佛医学院肺科担任职员职位，在那里她创立并指导了成人囊性纤维化项目。Ruddy博士拥有普林斯顿大学的学士学位和圣路易斯华盛顿大学的医学博士和医学硕士学位，并在哈佛医学院附属医院完成了她的内科和肺部研究金培训。
- Marcella Kuhlman Ruddy,has served as a member of Sionna Therapeutics, Inc. board of directors since January 2025. Dr. Ruddy has over 20 years of experience in drug development. Dr. Ruddy has served as the chief medical officer of Tectonic Therapeutic, Inc. (NASDAQ: TECX) since July 2021. From June 2016 to June 2021, Dr. Ruddy served as vice president of clinical development, immunology at Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), where she oversaw the clinical development of Dupixent. She is a trained pulmonologist who founded and led the Adult Cystic Fibrosis center at Massachusetts General Hospital, Boston from 1999-2004 prior to starting her drug development career at Merck & Co Inc. (NYSE: MRK). Dr. Ruddy has served on the board of directors of Upstream Bio, Inc. (NASDAQ: UPB) since January 2023. Dr. Ruddy previously served on the board of directors of Polarean, Inc. from August 2022 to June 2024. Dr. Ruddy received her B.A. in history from Princeton University and her M.D. and M.S. from Washington University, School of Medicine, St. Louis.
- Paul Clancy
-
Paul Clancy，2005年加入Atlas Venture，现任普通合伙人。他还担任或曾担任武田制药有限公司（NYSE：TAK）、UCB生物制药公司和比尔及梅林达·盖茨基金会的各种职务的顾问。Booth博士与人共同创立了Kymera，自2016年4月起担任其董事会主席。他还自2020年6月起担任Vigil Neuroscience, Inc.（NASDAQ：VIGIL）的董事长。Booth博士是多家私营公司的董事会主席或成员，包括Nimbus Therapeutics，LLC、Hotspot Therapeutics，Inc.、Arkuda Therapeutics，Inc.和Matchpoint Therapeutics，Inc.。Booth博士曾于2016年2月至2024年6月期间在AVROBIO，Inc.（现为Tectonic Therapeutic，Inc.（纳斯达克股票代码：TECX））的董事会任职，于2016年2月至2023年6月期间在Magenta Therapeutics, Inc.（现为Dianthus Therapeutics，Inc.（纳斯达克股票代码：DNTH））和Unum Therapeutics，Inc.（现为Cogent Biosciences, Inc.，TERM2（纳斯达克股票代码：COGT））的董事会任职，并于2014年10月至2020年7月期间在多家私营公司任职。Booth博士以优异成绩获得宾夕法尼亚州立大学生物化学学士学位。Booth博士是英国马歇尔学者，曾获得牛津大学纳菲尔德医学系分子免疫学博士学位。
Paul Clancy,has served as chair of Sionna Therapeutics, Inc. board of directors since June 2022. Mr. Clancy is currently a visiting senior lecturer of Finance at Cornell University's Graduate School of Management, where he has been employed since August 2020, and has been an executive fellow at Harvard Business School since July 2020. Previously, Mr. Clancy served as executive vice president and senior advisor at Alexion Pharmaceutical, Inc. (NASDAQ: ALXN) from November 2019 to July 2020 and executive vice president and chief financial officer from July 2017 to October 2019. Mr. Clancy also served as executive vice president and chief financial officer of Biogen, Inc. (NASDAQ: BIIB) from August 2007 to June 2017. Mr. Clancy also serves on the boards of directors of Exact Sciences Corporation (NASDAQ: EXAS), since March 2021, Xilio Therapeutics, Inc. (NASDAQ: XLO), since July 2020, and Incyte Corporation (NASDAQ: INCY), since 2015. Mr. Clancy previously served on the board of directors of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from September 2013 to June 2023. Mr. Clancy earned a B.S. in finance from Babson College and an M.B.A. from Columbia University. - Paul Clancy，2005年加入Atlas Venture，现任普通合伙人。他还担任或曾担任武田制药有限公司（NYSE：TAK）、UCB生物制药公司和比尔及梅林达·盖茨基金会的各种职务的顾问。Booth博士与人共同创立了Kymera，自2016年4月起担任其董事会主席。他还自2020年6月起担任Vigil Neuroscience, Inc.（NASDAQ：VIGIL）的董事长。Booth博士是多家私营公司的董事会主席或成员，包括Nimbus Therapeutics，LLC、Hotspot Therapeutics，Inc.、Arkuda Therapeutics，Inc.和Matchpoint Therapeutics，Inc.。Booth博士曾于2016年2月至2024年6月期间在AVROBIO，Inc.（现为Tectonic Therapeutic，Inc.（纳斯达克股票代码：TECX））的董事会任职，于2016年2月至2023年6月期间在Magenta Therapeutics, Inc.（现为Dianthus Therapeutics，Inc.（纳斯达克股票代码：DNTH））和Unum Therapeutics，Inc.（现为Cogent Biosciences, Inc.，TERM2（纳斯达克股票代码：COGT））的董事会任职，并于2014年10月至2020年7月期间在多家私营公司任职。Booth博士以优异成绩获得宾夕法尼亚州立大学生物化学学士学位。Booth博士是英国马歇尔学者，曾获得牛津大学纳菲尔德医学系分子免疫学博士学位。
- Paul Clancy,has served as chair of Sionna Therapeutics, Inc. board of directors since June 2022. Mr. Clancy is currently a visiting senior lecturer of Finance at Cornell University's Graduate School of Management, where he has been employed since August 2020, and has been an executive fellow at Harvard Business School since July 2020. Previously, Mr. Clancy served as executive vice president and senior advisor at Alexion Pharmaceutical, Inc. (NASDAQ: ALXN) from November 2019 to July 2020 and executive vice president and chief financial officer from July 2017 to October 2019. Mr. Clancy also served as executive vice president and chief financial officer of Biogen, Inc. (NASDAQ: BIIB) from August 2007 to June 2017. Mr. Clancy also serves on the boards of directors of Exact Sciences Corporation (NASDAQ: EXAS), since March 2021, Xilio Therapeutics, Inc. (NASDAQ: XLO), since July 2020, and Incyte Corporation (NASDAQ: INCY), since 2015. Mr. Clancy previously served on the board of directors of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) from September 2013 to June 2023. Mr. Clancy earned a B.S. in finance from Babson College and an M.B.A. from Columbia University.
- H. Edward Fleming, Jr.
-
H. Edward Fleming，Jr.于2022年11月加入Enavate Sciences，担任商业化执行副总裁，投资和建立治疗公司。此前，在2022年，弗莱明博士从麦肯锡公司退休，他在麦肯锡公司担任了26年的各种职务，包括高级合伙人、全球研发负责人和高级顾问。Fleming博士还自2023年6月起担任Upstream Bio，Inc.（NASDAQ：UPB）的董事会成员，自2021年6月起担任CRISPR Therapeutics AG（NASDAQ：CRSP）的董事会成员。此外，Fleming博士是多家私营公司的董事会成员，包括Komodo Health，Inc.、Orso Bio，Inc.、Sudo Biosciences，Inc.和Egnite，Inc.，并担任范德比尔特基础科学学院访客委员会成员。弗莱明博士获得了哈佛大学化学学士学位和范德比尔特大学医学博士学位，并在约翰霍普金斯医院完成了内科培训，在加州大学旧金山分校完成了肺部和重症医学的亚专科培训。
H. Edward Fleming, Jr.,has served as a member of Sionna Therapeutics, Inc. board of directors since March 2024. Dr. Fleming joined Enavate Sciences in November 2022 and serves as executive vice president of commercialization, investing in and building therapeutic companies. Previously, in 2022, Dr. Fleming retired from McKinsey & Company, where he worked for 26 years in various roles, including senior partner, global leader of research and development and senior advisor. Dr. Fleming has also served on the boards of directors of Upstream Bio, Inc. (NASDAQ: UPB) since June 2023 and of CRISPR Therapeutics AG (NASDAQ: CRSP) since June 2021. In addition, Dr. Fleming is a member of the boards of directors of several private companies, including Komodo Health, Inc., Orso Bio, Inc., Sudo Biosciences, Inc. and Egnite, Inc., and serves on the board of visitors of Vanderbilt's School of Basic Sciences. Dr. Fleming earned a B.A. in chemistry from Harvard University and an M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. - H. Edward Fleming，Jr.于2022年11月加入Enavate Sciences，担任商业化执行副总裁，投资和建立治疗公司。此前，在2022年，弗莱明博士从麦肯锡公司退休，他在麦肯锡公司担任了26年的各种职务，包括高级合伙人、全球研发负责人和高级顾问。Fleming博士还自2023年6月起担任Upstream Bio，Inc.（NASDAQ：UPB）的董事会成员，自2021年6月起担任CRISPR Therapeutics AG（NASDAQ：CRSP）的董事会成员。此外，Fleming博士是多家私营公司的董事会成员，包括Komodo Health，Inc.、Orso Bio，Inc.、Sudo Biosciences，Inc.和Egnite，Inc.，并担任范德比尔特基础科学学院访客委员会成员。弗莱明博士获得了哈佛大学化学学士学位和范德比尔特大学医学博士学位，并在约翰霍普金斯医院完成了内科培训，在加州大学旧金山分校完成了肺部和重症医学的亚专科培训。
- H. Edward Fleming, Jr.,has served as a member of Sionna Therapeutics, Inc. board of directors since March 2024. Dr. Fleming joined Enavate Sciences in November 2022 and serves as executive vice president of commercialization, investing in and building therapeutic companies. Previously, in 2022, Dr. Fleming retired from McKinsey & Company, where he worked for 26 years in various roles, including senior partner, global leader of research and development and senior advisor. Dr. Fleming has also served on the boards of directors of Upstream Bio, Inc. (NASDAQ: UPB) since June 2023 and of CRISPR Therapeutics AG (NASDAQ: CRSP) since June 2021. In addition, Dr. Fleming is a member of the boards of directors of several private companies, including Komodo Health, Inc., Orso Bio, Inc., Sudo Biosciences, Inc. and Egnite, Inc., and serves on the board of visitors of Vanderbilt's School of Basic Sciences. Dr. Fleming earned a B.A. in chemistry from Harvard University and an M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco.
- Joanne Louise Viney
-
Joanne Louise Viney是联合创始人，自2021年10月起担任Seismic Therapeutic（“Seismic”）的首席执行官。在此之前，Viney博士于2017年3月至2021年10月共同创立并担任Pandion Therapeutics, Inc.（NASDAQ：PAND）（“Pandion”）（被默沙东 & Co Inc.（NYSE：MRK）收购）的首席科学官。Viney博士目前在几家私营公司的董事会任职，包括Seismic和LabCentral。Viney博士此前曾于2021年3月至2024年3月在Graphite Bio, Inc.（纳斯达克股票代码：GRPH）（现为Lenz Therapeutics，Inc.（纳斯达克股票代码：LENZ））的董事会任职，于2020年7月至2023年6月在Harpoon Therapeutics, Inc.（纳斯达克股票代码：HARP）任职，于2019年8月至2023年3月在Finch Therapeutics Group, Inc.TERM3（纳斯达克股票代码：FNCH）以及多家私营公司的董事会任职。Viney博士在东伦敦大学获得生物物理科学荣誉学士学位，在伦敦大学圣巴塞洛缪医院医学院获得博士学位。
Joanne Louise Viney,has served as a member of Sionna Therapeutics, Inc. board of directors since January 2025. Dr. Viney is a co-founder and has served as the chief executive officer of Seismic Therapeutic ("Seismic") since October 2021. Prior to that, Dr. Viney co-founded and served as the chief scientific officer of Pandion Therapeutics, Inc. (NASDAQ: PAND) ("Pandion") (acquired by Merck & Co Inc. (NYSE: MRK)) from March 2017 to October 2021. Dr. Viney currently serves on the boards of directors of several private companies, including Seismic and LabCentral. Dr. Viney previously served on the boards of directors of Graphite Bio, Inc. (NASDAQ: GRPH) (now Lenz Therapeutics, Inc. (NASDAQ: LENZ)) from March 2021 to March 2024, Harpoon Therapeutics, Inc. (NASDAQ: HARP) from July 2020 to June 2023, Finch Therapeutics Group, Inc. (NASDAQ: FNCH) from August 2019 to March 2023 and several private companies. Dr. Viney received her B.Sc. with Honors in biophysical science from the University of East London and her Ph.D. from the University of London, St. Bartholomew's Hospital Medical School. - Joanne Louise Viney是联合创始人，自2021年10月起担任Seismic Therapeutic（“Seismic”）的首席执行官。在此之前，Viney博士于2017年3月至2021年10月共同创立并担任Pandion Therapeutics, Inc.（NASDAQ：PAND）（“Pandion”）（被默沙东 & Co Inc.（NYSE：MRK）收购）的首席科学官。Viney博士目前在几家私营公司的董事会任职，包括Seismic和LabCentral。Viney博士此前曾于2021年3月至2024年3月在Graphite Bio, Inc.（纳斯达克股票代码：GRPH）（现为Lenz Therapeutics，Inc.（纳斯达克股票代码：LENZ））的董事会任职，于2020年7月至2023年6月在Harpoon Therapeutics, Inc.（纳斯达克股票代码：HARP）任职，于2019年8月至2023年3月在Finch Therapeutics Group, Inc.TERM3（纳斯达克股票代码：FNCH）以及多家私营公司的董事会任职。Viney博士在东伦敦大学获得生物物理科学荣誉学士学位，在伦敦大学圣巴塞洛缪医院医学院获得博士学位。
- Joanne Louise Viney,has served as a member of Sionna Therapeutics, Inc. board of directors since January 2025. Dr. Viney is a co-founder and has served as the chief executive officer of Seismic Therapeutic ("Seismic") since October 2021. Prior to that, Dr. Viney co-founded and served as the chief scientific officer of Pandion Therapeutics, Inc. (NASDAQ: PAND) ("Pandion") (acquired by Merck & Co Inc. (NYSE: MRK)) from March 2017 to October 2021. Dr. Viney currently serves on the boards of directors of several private companies, including Seismic and LabCentral. Dr. Viney previously served on the boards of directors of Graphite Bio, Inc. (NASDAQ: GRPH) (now Lenz Therapeutics, Inc. (NASDAQ: LENZ)) from March 2021 to March 2024, Harpoon Therapeutics, Inc. (NASDAQ: HARP) from July 2020 to June 2023, Finch Therapeutics Group, Inc. (NASDAQ: FNCH) from August 2019 to March 2023 and several private companies. Dr. Viney received her B.Sc. with Honors in biophysical science from the University of East London and her Ph.D. from the University of London, St. Bartholomew's Hospital Medical School.
- Peter A. Thompson
-
Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
- Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Bruce Booth
-
Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University. - Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
- Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Elena Ridloff
Elena Ridloff自2020年9月起担任我们的董事会成员。Ridloff女士目前是Acadia PharmaceuticalsInc.首席财务官执行Vice PresidentAcadia，一家公开交易的制药公司。Ridloff女士此前曾高级副总裁，Acadia的投资者关系和临时首席财务官，自2018年4月以来一直在Acadia任职。在此之前，里德洛夫女士曾在亚力兄制药公司（Alexion）担任多个职位，包括2014年4月至2016年1月担任投资者关系执行董事，2016年1月至2018年3月担任投资者关系Vice President。Ridloff女士还担任Alexion’；s运营委员会的成员。任职Alexion公司期间，Ridloff女士负责建立和领导投资者关系职能部门。加入Alexion之前，Ridloff从2012年1月到2014年4月担任BioVisio（一家独立咨询公司，为生命科学行业提供战略、金融和投资者关系顾问）首席执行官和管理成员。Ridloff女士还于2005年7月至2012年1月担任Maverick Capital的董事总经理，该公司是一家对冲基金，负责生物技术，制药，医疗器械和生命科学领域的投资。Ridloff女士在宾夕法尼亚大学（University of Pennsylvania）获得历史与科学社会学学士学位，并是一名特许金融分析师。
Elena Ridloff,has served as Sionna Therapeutics, Inc. Chief Financial Officer and Head of Corporate Development since September 2021. Previously, Ms. Ridloff served in multiple roles at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from 2018 to 2021, including most recently as chief financial officer from October 2018 to September 2021. Ms. Ridloff has also served on the board of directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ("Kymera"), since March 2021 and Kronos Bio, Inc. (NASDAQ: KRON) since September 2020. Ms. Ridloff earned a B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst.- Elena Ridloff自2020年9月起担任我们的董事会成员。Ridloff女士目前是Acadia PharmaceuticalsInc.首席财务官执行Vice PresidentAcadia，一家公开交易的制药公司。Ridloff女士此前曾高级副总裁，Acadia的投资者关系和临时首席财务官，自2018年4月以来一直在Acadia任职。在此之前，里德洛夫女士曾在亚力兄制药公司（Alexion）担任多个职位，包括2014年4月至2016年1月担任投资者关系执行董事，2016年1月至2018年3月担任投资者关系Vice President。Ridloff女士还担任Alexion’；s运营委员会的成员。任职Alexion公司期间，Ridloff女士负责建立和领导投资者关系职能部门。加入Alexion之前，Ridloff从2012年1月到2014年4月担任BioVisio（一家独立咨询公司，为生命科学行业提供战略、金融和投资者关系顾问）首席执行官和管理成员。Ridloff女士还于2005年7月至2012年1月担任Maverick Capital的董事总经理，该公司是一家对冲基金，负责生物技术，制药，医疗器械和生命科学领域的投资。Ridloff女士在宾夕法尼亚大学（University of Pennsylvania）获得历史与科学社会学学士学位，并是一名特许金融分析师。
- Elena Ridloff,has served as Sionna Therapeutics, Inc. Chief Financial Officer and Head of Corporate Development since September 2021. Previously, Ms. Ridloff served in multiple roles at Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) from 2018 to 2021, including most recently as chief financial officer from October 2018 to September 2021. Ms. Ridloff has also served on the board of directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) ("Kymera"), since March 2021 and Kronos Bio, Inc. (NASDAQ: KRON) since September 2020. Ms. Ridloff earned a B.A. in history and sociology of science from the University of Pennsylvania and is a Chartered Financial Analyst.
- Michael Cloonan
Michael Cloonan，自2024年起在bluebird bio, Inc.董事会任职。自2021年5月以来，Cloonan先生在Sionna Therapeutics担任总裁兼首席执行官，领导公司战略和运营。2017年5月至2021年4月，Cloonan先生在Sage Therapeutics担任首席运营官，领导所有业务职能（商业、医疗事务、政府事务、业务发展、技术运营、战略和项目管理）以及一般和行政职能。在加入Sage之前，Cloonan先生在渤健担任了十四年的各种商业和商业职务，包括最近担任美国商业高级副总裁，担任价值数十亿美元的多发性硬化症、血友病和脊髓性肌萎缩症特许经营权的总经理。在加入渤健之前，Cloonan先生曾在贝恩公司担任顾问，专门从事医疗保健方面的工作。克鲁南先生获得了弗吉尼亚大学达顿工商管理研究生院的工商管理硕士学位和圣十字学院的学士学位。
Michael Cloonan,has served as Sionna Therapeutics, Inc. President, Chief Executive Officer and a member of Sionna Therapeutics, Inc. board of directors since May 2021. Previously, Mr. Cloonan served as the Chief Operating Officer of Sage Therapeutics, Inc. (NASDAQ: SAGE) ("Sage") from May 2020 to May 2021, and as the chief business officer of Sage from April 2017 to May 2020. Prior to joining Sage, Mr. Cloonan served in various leadership positions at Biogen, Inc. (NASDAQ: BIIB) ("Biogen") in various business and commercial roles in his fourteen years at Biogen. His most recent role at Biogen was as senior vice president, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia and SMA franchises. Mr. Cloonan has also served on the board of directors of bluebird bio, Inc. (NASDAQ: BLUE) since June 2024. Mr. Cloonan earned a B.A. in economics and accounting from the College of the Holy Cross and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.- Michael Cloonan，自2024年起在bluebird bio, Inc.董事会任职。自2021年5月以来，Cloonan先生在Sionna Therapeutics担任总裁兼首席执行官，领导公司战略和运营。2017年5月至2021年4月，Cloonan先生在Sage Therapeutics担任首席运营官，领导所有业务职能（商业、医疗事务、政府事务、业务发展、技术运营、战略和项目管理）以及一般和行政职能。在加入Sage之前，Cloonan先生在渤健担任了十四年的各种商业和商业职务，包括最近担任美国商业高级副总裁，担任价值数十亿美元的多发性硬化症、血友病和脊髓性肌萎缩症特许经营权的总经理。在加入渤健之前，Cloonan先生曾在贝恩公司担任顾问，专门从事医疗保健方面的工作。克鲁南先生获得了弗吉尼亚大学达顿工商管理研究生院的工商管理硕士学位和圣十字学院的学士学位。
- Michael Cloonan,has served as Sionna Therapeutics, Inc. President, Chief Executive Officer and a member of Sionna Therapeutics, Inc. board of directors since May 2021. Previously, Mr. Cloonan served as the Chief Operating Officer of Sage Therapeutics, Inc. (NASDAQ: SAGE) ("Sage") from May 2020 to May 2021, and as the chief business officer of Sage from April 2017 to May 2020. Prior to joining Sage, Mr. Cloonan served in various leadership positions at Biogen, Inc. (NASDAQ: BIIB) ("Biogen") in various business and commercial roles in his fourteen years at Biogen. His most recent role at Biogen was as senior vice president, U.S. Commercial, where he was the general manager of the multi-billion dollar MS, hemophilia and SMA franchises. Mr. Cloonan has also served on the board of directors of bluebird bio, Inc. (NASDAQ: BLUE) since June 2024. Mr. Cloonan earned a B.A. in economics and accounting from the College of the Holy Cross and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.
- Charlotte McKee
Charlotte McKee，于2014年6月至2020年3月在福泰制药（纳斯达克股票代码：VRTX）担任副总裁，负责囊性纤维化和Alpha-1抗胰蛋白酶缺乏症的临床开发。McKee博士在哈佛大学获得了历史和科学学士学位，在哥伦比亚大学获得了历史硕士学位，在哥伦比亚大学Vagelos内科医生和外科医生学院获得了医学博士学位，并在约翰霍普金斯大学医学院完成了内科培训和肺部和重症监护奖学金。
Charlotte McKee,has served as Sionna Therapeutics, Inc. Chief Medical Officer since June 2021. Previously, Dr. McKee served as vice president, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency Clinical Development at Vertex (NASDAQ: VRTX), from June 2014 to March 2020. Dr. McKee earned a B.A. in history and science from Harvard University, an M.A. in history from Columbia University and an M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed internal medicine training and a pulmonary and critical care fellowship at Johns Hopkins University School of Medicine.- Charlotte McKee，于2014年6月至2020年3月在福泰制药（纳斯达克股票代码：VRTX）担任副总裁，负责囊性纤维化和Alpha-1抗胰蛋白酶缺乏症的临床开发。McKee博士在哈佛大学获得了历史和科学学士学位，在哥伦比亚大学获得了历史硕士学位，在哥伦比亚大学Vagelos内科医生和外科医生学院获得了医学博士学位，并在约翰霍普金斯大学医学院完成了内科培训和肺部和重症监护奖学金。
- Charlotte McKee,has served as Sionna Therapeutics, Inc. Chief Medical Officer since June 2021. Previously, Dr. McKee served as vice president, Cystic Fibrosis and Alpha-1 Antitrypsin Deficiency Clinical Development at Vertex (NASDAQ: VRTX), from June 2014 to March 2020. Dr. McKee earned a B.A. in history and science from Harvard University, an M.A. in history from Columbia University and an M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed internal medicine training and a pulmonary and critical care fellowship at Johns Hopkins University School of Medicine.